JPMorgan downgraded Prime Medicine (PRME) to Neutral from Overweight without a price target The company announced that it is deprioritizing its chronic granulomatous disease program, turning over leadership and reducing headcount, the analyst tells investors in a research note. The firm says that while the strategic prioritization looks “prudent,” Prime’s resulting clinical catalyst outlook gets pushed back beyond its current first half of 2026 cash runway. With net cash $1 per share, the stock will like be range bound pending better visibility on development timelines and reach within key pipeline programs, contends JPMorgan.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRME:
- Prime Medicine price target lowered to $12 from $16 at Chardan
- Prime Medicine Appoints New CEO Amid Restructuring
- Prime Medicine, Inc.: Strategic Shifts and Leadership Changes Bolster Long-term Buy Rating Amid Near-term Volatility
- Prime Medicine CEO Keith Gottesdiener to step down, Allan Reine to succeed
- Prime Medicine to deprioritize CGD programs, reduce headcount by 25%